5 ways legal recruiting is changing, from how firms hire partners and hot practice areas. Top recruiters lay out what this means for the year ahead.

News, market analysis, investment scam prevention tips and more ✔️ Your source for latest asset management news and information. This magazine is crafted specifically for those who are interested in diving into the global asset management world. Insider spoke with seven recruiters about how legal recruiting is changing, from an increased attention to diverse hires and in-demand practice areas. Parker + Lynch; Major, Lindsey & Africa; Lateral LinkLegal industry recruiters have seen an uptick in searches for certain lawyers. Attorneys in tech, healthcare, and restructuring have been in demand, and M&A and white-collar work is expected to pick up in 2021. Some firms took advantage of the opportunity to strategically hire partners, and this trend is likely to continue in the year ahead. Visit Business Insider's homepage for more stories. Like virtually every other industry, the legal sector felt the initial shockwaves of the pandemic. Earlier last year, law firms pulled the trigger on layoffs, furloughs, and pay cuts, while certain practice areas saw a slow-down in work as clients sought to reduce spending. And, while legal recruiting didn't escape unscathed, especially in the earlier months - total hiring in 2020 was down by almost 28% compared to the previous year, per data from Firm Prospects - the situation quickly stabilized. "The legal industry as a whole has realized that it hasn't been hit as hard as everyone thought they would've been," said Meredith Frank, a To keep reading about 5 ways legal recruiting is changing, from how firms hire partners and hot practice areas. Top recruiters lay out what this means for the year ahead., Click on the link. Seoul, Korea
http://dlvr.it/Rr3XK5

Comments

Popular posts from this blog

AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts

Coronavirus Hasn't Diminished Tech Stocks' Allure

Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint